Evaxion A/S

What they do

Evaxion is a biological products company that applies artificial intelligence to discover and develop vaccine candidates and immunotherapies. Its pipeline is preclinical and clinical-stage, and it has monetized its platform through option and license agreements with partners. Operating costs are R&D and administrative, funded largely by equity issuances, warrants and a loan from the European Investment Bank. The company is listed in the U.S. through American Depositary Shares.

Revenue drivers

• MSD option and license agreement — An option and license agreement with MSD (signed September 2024, referenced again in September 2025) is the main disclosed partnering arrangement; the filing excerpts do not quantify the fees or milestones.
• Grant and collaboration income — The excerpts do not break out any grant, collaboration or license revenue line, so no segment size can be stated.
• Equity and warrant financing — Cash has come from repeated issuances — including 2023 SPA investor warrants, 2024 investor warrants and a January 2025 warrant issuance — rather than from product sales.
• EIB debt facility — A loan from the European Investment Bank, with related EIB warrants dated 2022 and 2024, provides additional funding; amounts are not specified in the excerpts.

Recent performance

The excerpts do not include income statement figures for 2025, so no revenue or net loss number can be cited. The share count at December 31, 2025 was 417,010,756 ordinary shares, with 70,130,556 warrants outstanding as of that year end. The filing confirms a par value of approximately DKK 0.25 per share. Executive turnover has been significant: the CEO changed in June 2025 (Mr. Kanstrup stepped down) and again in November 2025 (Dr. Tayton-Martin appointed CEO), following earlier CFO and COO departures in 2024.

Strategy

Management's stated direction is to fund AI-driven vaccine and immunotherapy discovery through partnerships and capital markets rather than commercial sales. The MSD option and license agreement is the clearest example of this partnering model. Financing has relied on successive warrant and equity issuances plus the EIB facility. The company also describes a risk-based cybersecurity program aligned with industry standards and applied to third-party providers. The excerpts do not disclose specific pipeline milestones, timelines or cash runway.

Risks

• No product revenue — The company is pre-commercial and the excerpts show no revenue line, so operations depend on external financing.
• Dilution from financings — 417,010,756 ordinary shares and 70,130,556 warrants were outstanding at year end, reflecting repeated equity and warrant issuance to fund operations.
• Executive turnover — The CEO role changed twice within 2025 — Mr. Kanstrup stepped down June 30, 2025 and Dr. Tayton-Martin was appointed November 24, 2025 — alongside 2024 departures of the CFO and COO.
• Partner concentration — Value depends heavily on a small number of arrangements such as the MSD option and license agreement, whose economics are not disclosed in the excerpts.

Outlook

Management does not provide quantified guidance in the excerpts. The disclosed priorities are advancing the AI-driven pipeline and monetizing it through partners such as MSD. Funding is expected to continue through warrant, equity and EIB-related instruments. The excerpts contain no cash runway, milestone or timeline figures.